Acurx Pharmaceuticals, Inc. (ACXP) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.36

From 52W high−82.84%

Volume54923.00

Market cap$7.61M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$1.36

From 52W high

−82.84%

Volume

54923.00

Market cap

$7.61M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.4x

P/E (TTM)

—

RSI (14)

45.9

MomentumView details →

1D Return

+0.00%

YTD Return

−43.98%

SummaryUpdated Jun 1, 2026

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Staten Island, New York. The company went public in June 2021 and focuses on developing novel antibiotics to treat serious bacterial infections. Acurx's primary focus is advancing its lead drug candidate, ibezapolstat, through clinical trials for treating Clostridium difficile infections, a potentially life-threatening condition that affects hundreds of thousands of patients annually.

Ask drillr about Acurx Pharmaceuticals, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.9x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−92.08%

ROA (TTM)

−68.33%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+66.98%

FCF YoY

+24.25%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+69.76%

EBITDA YoY

—

MomentumView details →

1D Return

+0.00%

YTD Return

−43.98%

1Y Return

−65.98%

RSI (14)

45.9

vs 50D SMA

−4.60%

vs 200D SMA

−39.06%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

3.88x

Quick Ratio

3.88x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.53

EPS Surprise

−40.71%

Beats (12Q)

6/12

Next Q EPS Est

−$0.38

Avg Surprise (4Q)

−130991.83%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−7.51M

Op. CF (TTM)

−6.18M

Next earningsNov 11, 2026 →

Latest newsMore news →

Acurx Pharmaceuticals received conditional acceptance from the FDA and trademark allowance from the USPTO for the brand name CIFBEZY for its drug candidate ibezapolstat.34d ago

The FDA provided regulatory guidance to Acurx Pharmaceuticals in meeting minutes from a July 13, 2026 Type C Meeting, indicating openness to a single Phase 3 trial registration plan for ibezapolstat and agreeing that a successful IBZ-ASPIRE trial supported by the IBZ-PATHFINDER Phase 2 trial could allow an NDA filing for both treatment and reduction of recurrence of C. difficile infection.48d ago

Similar companies

Traws Pharma, Inc.TRAW Imunon, Inc.IMNN InMed Pharmaceuticals Inc.INM CNS Pharmaceuticals, Inc.CNSP Skye Bioscience, Inc.SKYE Evogene Ltd.EVGN Find similar companies →

Latest newsMore news →

Acurx Pharmaceuticals received conditional acceptance from the FDA and trademark allowance from the USPTO for the brand name CIFBEZY for its drug candidate ibezapolstat.34d ago The FDA provided regulatory guidance to Acurx Pharmaceuticals in meeting minutes from a July 13, 2026 Type C Meeting, indicating openness to a single Phase 3 trial registration plan for ibezapolstat and agreeing that a successful IBZ-ASPIRE trial supported by the IBZ-PATHFINDER Phase 2 trial could allow an NDA filing for both treatment and reduction of recurrence of C. difficile infection.48d ago